Paul M. Ridker

Brigham and Women's Hospital — United States

Medicine · Health Sciences

224h-index232.1kcitations1.4kworks22.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(420), Adipokines, Inflammation, and Metabolic Diseases(282), Diabetes, Cardiovascular Risks, and Lipoproteins(183), Atherosclerosis and Cardiovascular Diseases(137), Genetic Associations and Epidemiology(108)

Publications1.3k total

The value of low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) in guiding cardiovascular prevention
European Heart Journal·2025
C-reactive protein and cardiovascular risk in the general population
European Heart Journal·2025· 6 citedOpen Access
Abstract 4369104: Polygenic Risk-Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials
Circulation·2025
Abstract 4344084: Plasma Protein N-Glycosylation Profiles Are Associated with Future Cardiovascular Events: Analyses from the JUPITER and TNT Trials
Circulation·2025
Unsupervised Learning Analysis of Triglycerides, Inflammation, Cholesterol, and the Risks of Incident Cardiovascular Disease and Type 2 Diabetes in the Women's Health Study
Journal of the American Heart Association·2025Open Access
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Journal of the American College of Cardiology·2025· 34 cited
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk
Journal of the American College of Cardiology·2025· 1 cited
C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’
European Heart Journal·2025· 12 citedOpen Access
Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction
IJC Heart & Vasculature·2025· 1 citedOpen Access
A stitch in time: easily measured biomarkers to enhance cardiovascular risk prediction in primary prevention
European Heart Journal·2025· 1 cited
Statins for the “SMuRFLess But Inflamed”
JACC Basic to Translational Science·2025· 2 citedOpen Access
Editorial: Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design
Frontiers in Cardiovascular Medicine·2025Open Access
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the <scp>SURMOUNT</scp> ‐ <scp>MMO</scp> trial
Obesity·2025· 16 citedOpen Access
Colchicine for Cardiovascular Disease
Journal of the American College of Cardiology·2025· 7 cited
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
European Heart Journal·2025· 29 citedOpen Access
hsCRP, High-Risk Plaque, and Pan-Coronary Atherosclerosis
JACC: Cardiovascular Interventions·2025· 2 cited
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels
JACC Advances·2025Open Access
Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study
European Heart Journal·2025· 30 citedOpen Access
Statin effects on immunoglobulin-G glycomic architecture and the link to cardiovascular disease
2025Open Access
Expanding the triglyceride range in clinical trials: therapeutic opportunities
European Heart Journal·2025· 15 cited
page 1 of 64Next →

Frequent Co-authors

Nader Rifai(13), Charles H. Hennekens(10), Wolfgang Köenig(9), Peter Libby(9), Nancy R. Cook(9), Jean MacFadyen(8), Julie E. Buring(8), John J.P. Kastelein(7), Tom Thurén(6), Christie M. Ballantyne(6), Francisco Antônio Helfenstein Fonseca(6), Jacques Genest(6), Alberto Lorenzatti(6), James T. Willerson(6), Robert J. Glynn(6), Meir J. Stampfer(6), Giulia Renda(5), Peter Libby(5), Robert J. Glynn(4), Antonio M. Gotto(4)